ES2177293T3 - Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido. - Google Patents
Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido.Info
- Publication number
- ES2177293T3 ES2177293T3 ES99930567T ES99930567T ES2177293T3 ES 2177293 T3 ES2177293 T3 ES 2177293T3 ES 99930567 T ES99930567 T ES 99930567T ES 99930567 T ES99930567 T ES 99930567T ES 2177293 T3 ES2177293 T3 ES 2177293T3
- Authority
- ES
- Spain
- Prior art keywords
- beta
- composition
- methylbutiric
- hidroxi
- minimum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Una composición que comprende ácido -hidroxi-- metilbutírico (HMB), L-glutamina y L-arginina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/102,941 US6031000A (en) | 1998-06-23 | 1998-06-23 | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2177293T3 true ES2177293T3 (es) | 2002-12-01 |
Family
ID=22292520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES99930567T Expired - Lifetime ES2177293T3 (es) | 1998-06-23 | 1999-06-23 | Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido. |
Country Status (12)
Country | Link |
---|---|
US (1) | US6031000A (es) |
EP (1) | EP1089726B1 (es) |
JP (2) | JP5064609B2 (es) |
AU (1) | AU756353B2 (es) |
CA (1) | CA2334761C (es) |
DE (1) | DE69901396T2 (es) |
DK (1) | DK1089726T3 (es) |
ES (1) | ES2177293T3 (es) |
NO (2) | NO329914B1 (es) |
NZ (1) | NZ508395A (es) |
PL (1) | PL195623B1 (es) |
WO (1) | WO1999066917A2 (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3362350B2 (ja) * | 1997-10-16 | 2003-01-07 | 味の素株式会社 | 反芻動物の肥育方法 |
US20040220266A1 (en) * | 2002-09-09 | 2004-11-04 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
US20040106678A1 (en) * | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
US6812249B2 (en) * | 2003-03-04 | 2004-11-02 | Sal Abraham | Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use |
US20050215640A1 (en) * | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
EP1973426A2 (en) * | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
CN101316582A (zh) * | 2005-11-30 | 2008-12-03 | 雀巢技术公司 | 治疗肌肉损失的方法 |
CN102225060A (zh) | 2005-12-19 | 2011-10-26 | 雅培制药有限公司 | β-羟基-β-甲基丁酸盐在调节1-型和2-型细胞因子生成失衡中的应用 |
US7754693B2 (en) * | 2006-02-16 | 2010-07-13 | Young Hee Ko | Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
US8324175B2 (en) | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
US8815280B2 (en) * | 2008-12-09 | 2014-08-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9770424B2 (en) * | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
US9539224B2 (en) * | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
CA2750944C (en) * | 2009-01-29 | 2019-01-08 | Young Hee Ko | Compositions and methods for the treatment of cancer |
EP2289555A1 (en) * | 2009-08-24 | 2011-03-02 | OrgaNext Research B.V. | Method of treating frailty |
HUE032486T2 (en) * | 2009-12-18 | 2018-05-02 | Metabolic Tech Inc | An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB) |
US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
SG182812A1 (en) | 2010-01-29 | 2012-09-27 | Abbott Lab | Nutritional emulsions comprising calcium hmb |
CN102711522B (zh) | 2010-01-29 | 2015-09-09 | 雅培制药有限公司 | 包含hmb的无菌包装的营养液 |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
WO2013067485A1 (en) | 2011-11-03 | 2013-05-10 | University Of Florida Research Foundation, Inc. | Nutritional supplement for weight management |
CN103945858A (zh) * | 2011-11-21 | 2014-07-23 | 埃默斯医疗股份有限公司 | 用于治疗糖尿病和相关病症的方法和组合物 |
EP2802322B1 (en) | 2012-01-11 | 2018-02-28 | Abbott Laboratories | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
WO2014040067A1 (en) | 2012-09-10 | 2014-03-13 | Metabolic Technologies, Inc. | Composition of hmb and atp and methods of use |
SG11201502205SA (en) | 2012-09-21 | 2015-04-29 | Abbott Lab | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes |
WO2014047493A1 (en) * | 2012-09-21 | 2014-03-27 | Abbott Laboratories | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate and protein |
WO2014078459A1 (en) | 2012-11-13 | 2014-05-22 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
SG11201507390SA (en) * | 2013-03-14 | 2015-10-29 | Abbott Lab | Treatment of insulin resistance associated with prolonged physical inactivity |
RU2015143836A (ru) | 2013-03-15 | 2017-04-27 | Нусерт Сайенсиз, Инк. | Лейцин и никотиновая кислота для снижения уровня липидов |
US20150057350A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Fibrosis biomarkers and methods of using same |
AU2015222754B2 (en) | 2014-02-27 | 2020-06-25 | Nusirt Sciences Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
PT3302704T (pt) * | 2015-06-01 | 2023-02-13 | Metabolic Tech Llc | Composições e métodos de utilização de beta-hidroxi-beta-metilbutirato (hmb) para diminuir a massa gorda |
AU2016323779B2 (en) | 2015-09-16 | 2022-03-17 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
US10647653B2 (en) | 2015-11-19 | 2020-05-12 | Kyowa Hakko Bio Co., Ltd. | Crystal of monovalent cation salt of 3-hydroxyisovaleric acid and process for producing the crystal |
BR122023026038A2 (pt) | 2016-01-21 | 2024-01-16 | Metabolic Technologies, Inc. | Usos de um ácido e de um modulador de autofagia e de lipofagia |
WO2017184788A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
EP3476825A4 (en) | 2016-06-24 | 2020-02-26 | Kyowa Hakko Bio Co., Ltd. | BETA-HYDROXY BETA-METHYLBUTYRIC ACID AMINO ACID SALT CRYSTAL AND METHOD FOR PRODUCING THE SAME |
EP3528801A4 (en) | 2016-10-21 | 2020-07-15 | Metabolic Technologies, Inc. | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) AND PROBIOTICS |
JOP20190146A1 (ar) * | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
KR20200039748A (ko) | 2017-08-14 | 2020-04-16 | 악셀라 헬스 인크. | 간 질환 치료를 위한 아미노산 조성물 |
CN112105352A (zh) * | 2018-01-05 | 2020-12-18 | 得克萨斯理工大学研究商业化办公室 | 与间歇性禁食相关的β-羟基-β-甲基丁酸(HMB)组合物和使用方法 |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5157022A (en) * | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
NZ256300A (en) * | 1992-09-16 | 1997-06-24 | Univ Iowa State Res Found Inc | Administration of beta-hydroxy-beta-methyl butyric acid, or its convertible forms, to lower cholesterol levels |
US5348979A (en) * | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
AU6102994A (en) * | 1993-02-11 | 1994-08-29 | Iowa State University Research Foundation Inc. | Method of enhancing nutritional value of colostrum and first milk of pregnant mammals |
US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
US5756469A (en) * | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
DE29707308U1 (de) * | 1997-04-23 | 1997-06-26 | Kunz Armin | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
-
1998
- 1998-06-23 US US09/102,941 patent/US6031000A/en not_active Expired - Lifetime
-
1999
- 1999-06-23 CA CA002334761A patent/CA2334761C/en not_active Expired - Lifetime
- 1999-06-23 EP EP99930567A patent/EP1089726B1/en not_active Expired - Lifetime
- 1999-06-23 WO PCT/US1999/014097 patent/WO1999066917A2/en active IP Right Grant
- 1999-06-23 JP JP2000555603A patent/JP5064609B2/ja not_active Expired - Lifetime
- 1999-06-23 NZ NZ508395A patent/NZ508395A/en not_active IP Right Cessation
- 1999-06-23 DK DK99930567T patent/DK1089726T3/da active
- 1999-06-23 AU AU47080/99A patent/AU756353B2/en not_active Expired
- 1999-06-23 ES ES99930567T patent/ES2177293T3/es not_active Expired - Lifetime
- 1999-06-23 PL PL99344589A patent/PL195623B1/pl unknown
- 1999-06-23 DE DE69901396T patent/DE69901396T2/de not_active Expired - Lifetime
-
2000
- 2000-12-22 NO NO20006633A patent/NO329914B1/no not_active IP Right Cessation
-
2010
- 2010-10-18 NO NO20101440A patent/NO332374B1/no not_active IP Right Cessation
-
2011
- 2011-12-26 JP JP2011282771A patent/JP5690261B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69901396T2 (de) | 2002-08-29 |
PL344589A1 (en) | 2001-11-05 |
JP5064609B2 (ja) | 2012-10-31 |
EP1089726A2 (en) | 2001-04-11 |
JP2002518440A (ja) | 2002-06-25 |
NO20006633L (no) | 2001-02-20 |
AU756353B2 (en) | 2003-01-09 |
US6031000A (en) | 2000-02-29 |
NO329914B1 (no) | 2011-01-24 |
EP1089726B1 (en) | 2002-05-02 |
JP2012102118A (ja) | 2012-05-31 |
CA2334761C (en) | 2009-04-28 |
WO1999066917A2 (en) | 1999-12-29 |
DK1089726T3 (da) | 2002-07-22 |
DE69901396D1 (de) | 2002-06-06 |
PL195623B1 (pl) | 2007-10-31 |
NO20101440L (no) | 2001-02-20 |
JP5690261B2 (ja) | 2015-03-25 |
NO332374B1 (no) | 2012-09-10 |
NO20006633D0 (no) | 2000-12-22 |
CA2334761A1 (en) | 1999-12-29 |
NZ508395A (en) | 2003-09-26 |
WO1999066917A3 (en) | 2000-04-20 |
AU4708099A (en) | 2000-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2177293T3 (es) | Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido. | |
ATE289640T1 (de) | Amidofunktionelle aminopolydiorganosiloxane | |
MXPA05006629A (es) | Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador. | |
DE59913840D1 (de) | Effektoren von Dipeptidylpeptidase IV | |
TR200202194T2 (tr) | Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri | |
ATE264863T1 (de) | 28-epirapaloge | |
RS50729B (sr) | Preparat flastera induktora hipersenzitiviteta sa odloženim dejstvom i njegova primena | |
DE60120712D1 (en) | Kallikrein gen | |
UY25712A1 (es) | Benzamidas sustituidas y su aplicación en medicamentos | |
JO2212B1 (en) | 4-PDE inhibitors for ethan substituted with three Ariel groups | |
MXPA03010801A (es) | Material polimerico que contiene un acido latente. | |
CY1107297T1 (el) | Συνθεση με μυκητοκτονο δραση με βαση αλας καλιου του φωσφορωδους οξεος (potassium acid phosphite) | |
ES2181168T3 (es) | Mezclas solidas a base de sulfonilureas y adyuvantes. | |
BR0007922A (pt) | Compostos calcilìticos | |
ES2132539T3 (es) | Composiciones insecticidas sinergicas. | |
ES2184398T3 (es) | Mezclas herbicidas a base de aclonifeno y de clomazona. | |
EA200200091A1 (ru) | Содержащая амброксол пастилка | |
ATE283311T1 (de) | Vorvernetzungshemmende zusammensetzung | |
PL376130A1 (en) | Controlled releases system containing temozolomide | |
ATE242763T1 (de) | Methoximinophenylessigsäureamide | |
DK1126853T3 (da) | Kontrolleret levering af antidepressine midler | |
AP2000001945A0 (en) | Leishmania cysteine proteinases. | |
ATE238791T1 (de) | Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum | |
ATE270113T1 (de) | Zusammenstellungen zur verbesserten wundheilung | |
AR041373A1 (es) | Composicion y metodo para blanquear un sustrato |